The estimated Net Worth of E Kevin Hrusovsky is at least $20.9 millió dollars as of 12 June 2024. Mr. Hrusovsky owns over 7,777 units of Quanterix Corp stock worth over $1,689,112 and over the last 13 years he sold QTRX stock worth over $15,574,314. In addition, he makes $3,631,000 as Chairman of the Board, President és Chief Executive Officer at Quanterix Corp.
E has made over 96 trades of the Quanterix Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 7,777 units of QTRX stock worth $93,868 on 12 June 2024.
The largest trade he's ever made was exercising 76,016 units of Quanterix Corp stock on 21 November 2022 worth over $26,606. On average, E trades about 5,548 units every 23 days since 2012. As of 12 June 2024 he still owns at least 139,943 units of Quanterix Corp stock.
You can see the complete history of Mr. Hrusovsky stock trades at the bottom of the page.
E. Kevin Hrusovsky serves as Chairman of the Board, President, Chief Executive Officer of the Company. Prior to joining us, Mr. Hrusovsky served as Senior Vice President of PerkinElmer, Inc., a publicly traded company that produces analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments and consumables for multiple end markets, from February 2012 to May 2013 and served as President of the Life Sciences and Technology business unit of PerkinElmer, Inc. from November 2011 to May 2013. From May 2013 through September 2013, he served as a consultant to PerkinElmer. Previously, Mr. Hrusovsky served as Chief Executive Officer and President of Caliper Life Sciences, Inc., a life sciences company that developed and sold lab automation equipment, from July 2003 to November 2011 when it was acquired by PerkinElmer, Inc. Prior to that, he served as Chief Executive Officer and President of Zymark, a company that provided laboratory automation, robotics, and liquid handling solutions, and Director of International Business, Agricultural Chemical Division, and President of the Pharmaceutical Division for FMC Corporation, a publicly traded chemical manufacturing company. He also held several management positions at E.I. DuPont de Nemours, a publicly traded chemical manufacturing company. Mr. Hrusovsky serves on the boards of directors of several private companies, including BioreclamationIVT, LLC, Cellaria, Cell Signaling Technology, Inc., 908 Devices Inc., and Solect Energy Development, LLC, and is the founder of the Powering Precision Health Summit, an executive think tank of researchers, scientists, physicians and innovators focused on the latest research on new biomarkers that have the potential to advance personalized medicine.
As the Chairman of the Board, President és Chief Executive Officer of Quanterix Corp, the total compensation of E Hrusovsky at Quanterix Corp is $3,631,000. There are no executives at Quanterix Corp getting paid more.
E Hrusovsky is 58, he's been the Chairman of the Board, President és Chief Executive Officer of Quanterix Corp since 2015. There are 11 older and 9 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.
E's mailing address filed with the SEC is C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON, MA, 02210.
Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister és Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Quanterix Corp executives and other stock owners filed with the SEC include: